Pulmonary drug delivery: From generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges

The Lancet Respiratory Medicine

Volumn 1, Issue 5, 2013, Pages 402-413

  Ruge, Christian ^a   Kirch, Julian ^b   Lehr, Claus Michael ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; APOMORPHINE; BUDESONIDE; CALCITONIN; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; CYCLOSPORIN; DIHYDROERGOTAMINE MESILATE; DRUG CARRIER; ERYTHROPOIETIN; FENTANYL; FLUTICASONE PROPIONATE; HEPARIN; HUMAN GROWTH HORMONE; ITRACONAZOLE; LOXAPINE; LUNG SURFACTANT; MORPHINE; NICOTINE; PARATHYROID HORMONE; PENTAMIDINE; PROCHLORPERAZINE; RECOMBINANT HUMAN INSULIN; TOBRAMYCIN; VARENICLINE; AEROSOL;

AEROSOL; ANEMIA; ANXIETY DISORDER; ASTHMA; BEHAVIOR DISORDER; BIPOLAR I DISORDER; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; GROWTH HORMONE DEFICIENCY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG CLEARANCE; LUNG TUBERCULOSIS; MIGRAINE; MUCOCILIARY CLEARANCE; NANOPHARMACEUTICS; OSTEOPOROSIS; PARKINSON DISEASE; PERMEABILITY BARRIER; PRIORITY JOURNAL; PULMONARY DRUG DELIVERY; REVIEW; SCHIZOPHRENIA; TOBACCO DEPENDENCE; DEVICES; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG DISEASES; METABOLISM; PROCEDURES; THERAPEUTIC USE;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; LUNG DISEASES;

EID: 84881377924     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70072-9     Document Type: Review

References (88)

1. Patton JS, Brain JD, Davies LA, et al. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aersosol Med Pulm D 2010; 23: S71-87.
2. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: physiological factors aff ecting therapeutic eff ectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 588-99.
3. Patton JS. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-44.
4. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
5. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004; 1: 315-20.
6. Sturm R, Hofmann W. A theoretical approach to the deposition and clearance of fi bers with variable size in the human respiratory tract. J Hazard Mater 2009; 170: 210-18.
7. Olsson B, Bondesson E, Borgström L, et al. Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, eds. Controlled pulmonary drug delivery. New York: Springer New York, 2011: 21-50.
8. Armitage A, Dollery C, Houseman T, et al. Absorption of nicotine from small cigars. Clin Pharmacol Ther 1978; 23: 143-51.
9. Noymer P, Biondi S, Myers D, et al. Pulmonary delivery of therapeutic compounds for treating CNS disorders. Ther Deliv 2011; 2: 1125-40.
10. Alexza Pharmaceuticals Inc. Press release: U.S. FDA Approves Alexza's ADASUVE (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults, 2012. http://www.reuters.com/article/2012/12/21/ca-alexzapharmaceuti-idUSnPnSF32667+160+PRN20121221 (accessed Jan 21, 2013).
11. Islam N, Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther 2012; 6: 123-32.
12. Heinemann L. New ways of insulin delivery. Int J Clin Pract 2011; 170: 31-46.
13. Tuinman PR, Dixon B, Levi M, et al. Nebulized anticoagulants for acute lung injury-a systematic review of preclinical and clinical investigations. Crit Care 2012; 16: 70.
14. Siekmeier R, Scheuch G. Treatment of systemic diseases by inhalation of biomolecule aerosols. J Physiol Pharmacol 2009; 60: 15-26.
15. Forbes B, Asgharian B, Dailey LA, et al. Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliver Rev 2011; 63: 69-87.
16. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliver Rev 1996; 19: 3-36.
17. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release 2000; 65: 43-47.
18. Morales JO, Peters JI, Williams RO. Surfactants: their critical role in enhancing drug delivery to the lungs. Ther Deliv 2011; 2: 623-41.
19. Antunes MB, Cohen NA. Mucociliary clearance-a critical upper airway host defense mechanism and methods of assessment. Curr Opin Allergy Clin Immunol 2007; 7: 5-10.
20. Thornton DJ, Sheehan JK. From mucins to mucus: toward a more coherent understanding of this essential barrier. Proc Am Thorac Soc 2004; 1: 54-61.
21. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009; 135: 505-12.
22. Sanders N, Rudolph C, Braeckmans K, et al. Extracellular barriers in respiratory gene therapy. Adv Drug Deliver Rev 2009; 61: 115-27.
23. Antunes MB, Gudis DA, Cohen NA. Epithelium, cilia, and mucus: their importance in chronic rhinosinusitis. Immunol Allergy Clin North Am 2009; 29: 631-43.
24. Smith DJ, Gaffney EA, Blake JR. Modelling mucociliary clearance. Respir Physiol Neurobiol 2008; 163: 178-88.
25. Ryser M, Burn A, Wessel T, et al. Functional imaging of mucociliary phenomena: high-speed digital refl ection contrast microscopy. Eur Biophys J 2007; 37: 35-54.
26. Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010; 7: 1-17.
27. Geiser M, Cruz-Orive LM, Im Hof V, et al. Assessment of particle retention and clearance in the intrapulmonary conducting airways of hamster lungs with the fractionator. J Microsc 1990; 160: 75-88.
28. Randell SH, Boucher RC, Group UoNCVL. Eff ective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35: 20-28.
29. Geiser M. Update on macrophage clearance of inhaled micro-and nanoparticles. J Aersosol Med Pulm D 2010; 23: 207-17.
30. Bastacky J, Lee CY, Goerke J, et al. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J Appl Physiol 1995; 79: 1615-28.
31. Pérez-Gil J. Structure of pulmonary surfactant membranes and fi lms: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008; 1778: 1676-95.
32. Schürch S, Gehr P, Im Hof V, et al. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990; 80: 17-32.
33. Harishchandra RK, Saleem M, Galla H-J. Nanoparticle interaction with model lung surfactant monolayers. J R Soc Interface 2010; 7: S15-S26.
34. Chroneos ZC, Sever-Chroneos Z, Shepherd VL. Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem 2010; 25: 13-26.
35. Ruge CA, Kirch J, Cañadas O, et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomed-Nanotechnol 2011; 7: 690-93.
36. Ruge CA, Schaefer UF, Herrmann J, et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One 2012; 7: 40775.
37. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
38. Carvalho TC, Carvalho SR, McConville JT. Formulations for pulmonary administration of anticancer agents to treat lung malignancies. J Aersosol Med Pulm D 2011; 24: 61-80.
39. Zarogoulidis P, Zarogoulidis K, Domvri K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomed 2012; 7: 1551-72.
40. Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011; 91: 71-81.
41. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377: 1032-45.
42. Labiris N, Dolovich M. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic eff ectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 600-12.
43. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392: 1-19.
44. Perry JL, Herlihy KP, Napier ME, et al. PRINT: a novel platform toward shape and size specifi c nanoparticle theranostics. Acounts Chem Res 2011; 44: 990-98.
45. Garcia A, Mack P, Williams S, et al. Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv 2012; 2012: 1-10.
46. Kohler D, Schneider M, Krüger M, et al. Template-assisted polyelectrolyte encapsulation of nanoparticles into dispersible, hierarchically nanostructured microfi bers. Adv Mater 2011; 23: 1376-79.
47. Daum N, Tscheka C, Neumeyer A, et al. Novel approaches for drug delivery systems in nanomedicine: eff ects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 4: 52-65.
48. Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 2012; 161: 214-24.
49. Yang JZ, Young AL, Chiang P-C, et al. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008; 97: 4869-78.
50. Tolman JA, Williams RO. Advances in the pulmonary delivery of poorly water-soluble drugs: infl uence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm 2010; 36: 1-30.
51. Tsapis N, Bennett D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002; 99: 12001-05.
52. Islam N, Cleary MJ. Developing an effi cient and reliable dry powder inhaler for pulmonary drug delivery-a review for multidisciplinary researchers. Med Eng Phys 2012; 34: 409-27.
53. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009; 29: 196-212.
54. Sakagami M, Byron PR. Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic effi cacy. Clin Pharmacokinet 2005; 44: 263-77.
55. Lehr C-M, Poelma FGJ, Junginger HE, et al. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm 1991; 70: 235-40.
56. Makhlof A, Werle M, Tozuka Y, et al. Nanoparticles of glycol chitosan and its thiolated derivative signifi cantly improved the pulmonary delivery of calcitonin. Int J Pharm 2010; 397: 92-95.
57. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliver Rev 2001; 47: 39-54.
58. Wang Y-Y, Lai SK, Suk JS, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 2008; 47: 9726-29.
59. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009; 71: 505-18.
60. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliver Rev 2001; 52: 117-26.
61. Bernkop-Schnürch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliver Rev 2005; 57: 1569-82.
62. Rekha M, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes-future perspectives. Int J Pharm 2013; 440: 48-62.
63. Shahbazi MA, Santos HA. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 2013; 14: 28-56.
64. Lai SK, O'Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007; 104: 1482-87.
65. Kirch J, Guenther M, Doshi N, et al. Mucociliary clearance of micro-and nanoparticles is independent of size, shape and charge: an ex vivo and in silico approach. J Control Release 2012; 159: 128-34.
66. Kirch J, Schneider A, Abou B, et al. Optical tweezers reveal relationship between microstructure and nanoparticle penetration of pulmonary mucus. Proc Natl Acad Sci USA 2012; 109: 18355-60.
67. Kuhn SJ, Hallahan DE, Giorgio TD. Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng 2006; 34: 51-58.
68. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379-85.
69. El-Sherbiny IM, McGill S, Smyth HDC. Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci 2010; 99: 2343-56.
70. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009; 26: 244-49.
71. Anabousi S, Kleemann E, Bakowsky U, et al. Eff ect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol 2006; 6: 3010-16.
72. Carvalho TC, Peters JI, Williams III RO. Infl uence of particle size on regional lung deposition: what evidence is there? Int J Pharm 2011; 406: 1-10.
73. Kleinstreuer C, Seelecke S, inventors; North Carolina State University (Raleigh, NC) assignee. Inhaler system for targeted maximum drug-aerosol delivery. USA patent 7900625. 2011.
74. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 2008; 10: 195-220.
75. Pausley ME, Seelecke S. Multifunctional SMA-based smart inhaler system for improved aerosol drug delivery-design and fabrication. Proc SPIE 2008; published online April 4. DOI:10.1117/12.77621 2.
76. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007; 2: 495-99.
77. Master AM, Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomed 2012; 7: 1895-906.
78. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012; 2: 3-44.
79. Gaspar MM, Radomska A, Gobbo OL, et al. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J Aersosol Med Pulm D 2012; 25: 310-18.
80. Anabousi S, Bakowsky U, Schneider M, et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006; 29: 367-74.
81. Goren D, Horowitz AT, Tzemach D, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrugresistance effl ux pump. Clin Cancer Res 2000; 6: 1949-57.
82. Griffiths G, Nystr"m B, Sable SB, et al. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 2010; 8: 827-34.
83. Lawlor C, Kelly C, O'Leary S, et al. Cellular targeting and traffi cking of drug delivery systems for the prevention and treatment of MTb. Tuberculosis 2011; 91: 93-97.
84. Gill DR, Davies LA, Pringle IA, et al. The development of gene therapy for diseases of the lung. Cell Mol Life Sci 2004; 61: 355-68.
85. Aneja MK, Geiger J-P, Himmel A, et al. Targeted gene delivery to the lung. Expert Opin Drug Deliv 2009; 6: 567-83.
86. Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv 2012; 9: 1489-503.
87. Taetz S, Nafee N, Beisner J, et al. The infl uence of chitosan content in cationic chitosan/plga nanoparticles on the delivery effi ciency of antisense 2'-o-methyl-RNA directed against telomerase in lung cancer cells. Eur J Pharm Biopharm 2009; 72: 358-69.
88. Weers JG, Bell J, Chan H-K, et al. Pulmonary formulations: what remains to be done? J Aersosol Med Pulm D 2010; 23 (suppl 2): 5-23.